Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Gets Deficiency Notice from Nasdaq

NEW YORK (GenomeWeb News) – Compugen has received a letter from Nasdaq stating that the firm is currently not in compliance with listing regulations.

The Tel Aviv-based company said that it received the letter on May 28. The firm is not in compliance with regulations that state that it must have at least $10 million in stockholders' equity. As of March 31, Compugen had stockholders' equity of around $8.9 million.

Compugen, which currently trades on the Nasdaq Global Market Marketplace, said that it can either submit a detailed plan of compliance by June 15, or apply to transfer to the Nasdaq Capital Market.

The firm said that it believes that, as of today, it is in compliance with the listing requirements for the Nasdaq Capital Market.

In early Tuesday trade, Compugen's shares were up 4 percent at $1.30.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more